Our Story
EMBioSys was founded in 2022 with the goal of establishing a new treatment modality in the fight against cancer by delivering safe and effective induced electric field therapy (iEF Therapy) via non-invasive wearable garments.
Backed by over a decade of compelling pre-clinical studies, we are now planning a human clinical trial to offer new hope for women diagnosed with triple-negative breast cancer (TNBC). TNBC is an aggressive type of breast cancer with high mortality rates and limited treatment options.
In parallel with our work in breast cancer, we are building a roadmap to address other hard-to-treat solid cancers.
Our Mission
To commercialize novel, non-invasive electromagnetic therapies for solid cancers that improve patient quality of life, standard of care, and overall treatment outcomes
Our Vision
To aid in the realization of a future whereby treatment of solid cancers are no longer associated with harsh side effects, financial disparity, and shortened life expectancy
Our Products
Non-pharmacological, electrode-free wearable garments that inhibit solid cancer metastasis, while improving the efficacy of standard of care treatment outcomes
Honoring Joe West
The EMBioSys family sadly shares the news of our loss of one of our co-Founders, Joe West (https://www.dignitymemorial.com/obituaries/columbus-oh/joe-west-12438559#services). Joe was one of the co-inventors of Efinia™ and induced electric field (iEF) therapy, and a key contributor to EMBioSys’ prototyping, research, and development efforts.
Joe also significantly contributed to teaching, mentorship, and training of undergraduate and graduate students, curriculum development and support of faculty research during his more than three decades at The Ohio State University ( Click here to learn more about Joe's legacy at OSU). OSU is fundraising to set up a Joe West Memorial Fund to continue his work in perpetuity (Click on this link https://buckeyefunder.osu.edu/project/47083 to learn more about how to contribute to this Fund).
EMBioSys will continue to persevere to realize Joe’s and our collective dream of translating iEF therapy to the clinic for the benefit of cancer patients. We join the entire OSU community of alumni, students, staff, and faculty in recognizing his many contributions and extend our deepest condolences to Joe’s family.
Leadership
Chris Barron
Co-Founder & Chief Executive Officer
Co-Founder, President & Chief Scientific Officer
Vish Subramaniam, PhD
Jennifer Herron
Independent Board Member and Strategic Advisor
Advisory Board
Board Certified General Internist with 30 years of drug development experience in multiple areas, including oncology, inflammation, vaccines, neuroscience, and roles as head of clinical research and medical affairs
Joe Camardo, MD
Chair of Radiation Oncology at Weill Cornell Medicine; Radiation Oncologist-in-Chief at New York Presbyterian; Leader in cancer research and clinical trial innovation;
Expert in translating preclinical work to human studies
Silvia C. Formenti, MD
Specializes in radiation oncology, with focus on breast, skin, head and neck cancers at The James Comprehensive Cancer Center in Columbus, Ohio
Sachin Jhawar, MD
CFO with 30 years' experience in diverse industries including clinical-stage life science companies and medical device firms advancing pharma and biologics
therapies for cancer, retinal and kidney diseases
Rick Clemon, CPA, CGMA
Regulatory, Clinical and Quality executive with 30 years in medical device and pharma industries focused on strategic global product realization and compliant business processes worldwide
